Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Valneva Se ADR (NQ: VALN )

7.089 UNCHANGED
Streaming Delayed Price Updated: 2:47 PM EDT, Jun 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 7.089
Bid (Size) 6.730 (6)
Ask (Size) 11.40 (1)
Prev. Close 7.089
Today's Range 7.089 - 7.089
52wk Range 6.580 - 17.05
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What Analysts Are Saying About Valneva Stock
Via Benzinga
Valneva Seeks Expanded Use For Its Chikungunya Vaccine In Adolescents With Encouraging Phase 3 Data
Valneva released positive Phase 3 data for its single-shot chikungunya virus vaccine in adolescents. The vaccine is also expected to be approved for use in Brazil. 
Via Benzinga

Performance

YTD
-30.77%
-30.77%
1 Month
-19.81%
-19.81%
3 Month
-8.22%
-8.22%
6 Month
-31.52%
-31.52%
1 Year
-58.24%
-58.24%

More News

Read More
VALN Stock Earnings: Valneva Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Cracking The Code: Understanding Analyst Reviews For Valneva
Via Benzinga
What Analysts Are Saying About Valneva Stock
Via Benzinga
VALN Stock Earnings: Valneva Misses Revenue for Q4 2023
Via InvestorPlace
National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Expert Ratings for Valneva
Via Benzinga
Smith & Wesson Brands Reports Upbeat Earnings, Joins America's Car-Mart, HCI Group And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Novavax’s dispute resolution and upcoming earnings call
Via MarketBeat
Topics Earnings
Exposures COVID-19 Financial
Chikungunya Vaccine Maker Valneva Secures Non Dilutive Funding To Develop/Expand Its Clinical Pipeline
Via Benzinga
Exposures Product Safety
Analyst Ratings for Valneva
Via Benzinga
Analyst Ratings for Valneva
Via Benzinga
McDonald's, Caterpillar And 3 Stocks To Watch Heading Into Monday
Via Benzinga
Valneva Says Single Chikungunya Vaccine Shows Long-Lasting Antibody Response In Younger, Older Adults
Via Benzinga
FDA Approves World's First Mosquito-Borne Chikungunya Vaccine
Via Benzinga
Exposures Product Safety
Pfizer, Valneva's Tick-Borne Infection Shot: Companies Say 'Positive' Result For Lyme Disease Vaccine Candidate Booster
Via Benzinga
7 Unmatched Stocks: The Untapped Goldmines to Buy Now.
Via InvestorPlace
Why 22nd Century Group Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
AMC Entertainment, Nikola, Cleveland-Cliffs And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Top 5 Health Care Stocks That May Crash This Month
Via Benzinga
Bavarian Nordic Beefs Up Chikungunya Vaccine Race With Valneva With Encouraging Late-Stage Trial Data
Via Benzinga
DICE Therapeutics, Surmodics, Nikola, And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.